Afferent Pharmaceuticals Inc.
Targeting P2X3 for pain and other disorders
This article was originally published in Start Up
In drug development, the tiniest of targets sometimes prove windows of huge opportunity. For chronic pain start-up Afferent Pharmaceuticals Inc., a single receptor subfamily may hold the key to unlocking novel treatments for that tough-to-alleviate disorder and a remarkable number of other diseases.